Background:
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: May 2020: The following drug classes/subclass and newly approved agents will be reviewed:

Oncological Agents, SUB CLASS:  N/A - Ayvakit

Antipsychotic Agents, SUB CLASS:  Atypical - Caplyta

Antihemophilic Factors, SUB CLASS:  N/A - Esperoct

Migraine Agents, SUB CLASS:  N/A – Ubrelvy

Migraine Agents, SUB CLASS: Second Generation – Ubrelvy

Anticonvulsants-Antimania Agents, SUB CLASS: N/A - Valtoco

RFQ: The RFQ, including UF BPA and UF ADP appendices are attached herein. Pre-proposal teleconference is on February 12, 2020 details are stated in Part 2.5. Clinical Questions in Part 3.4 shall be submitted via e-mail to the RFQ Point of Contact stated in Part 2.3, no later than the date stated in Part 2.4.

POCs: Part 2.3 of the RFQ.

UPDATE as of 4/16/2020: Your company has submitted a price concession in support of the 2020 May P&T meeting.  As a result of the COVID-19 pandemic, we will be adjusting our 2020 May P&T meeting.  At this time, we expect to not complete the drug class reviews. We will only be reviewing newly approved drugs that have been posted to the health.mil/pandt website.  We will be reviewing the drugs from a cost perspective with the price submitted for the BPA and/or ADP quote.  Manufacturers that are being considered as part of the newly approved drug program need not take any action.  The BAP and Director DHA review of the newly approved drugs is expected to proceed as scheduled for this part and other actions that are considered as part of the May 2020 P&T meeting.